Pretax income is the income that a company earns before paying income taxes. Orchestra BioMed Holdings's pretax income for the
three
months ended in Mar. 2024 was $-13.46 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-51.64 Mil.
Orchestra BioMed Holdings's pretax margin was -2,171.45%.
During the past 4 years, Orchestra BioMed Holdings's highest Pretax Margin was 2942.97%. The lowest was -2330.46%. And the median was -662.86%.
Orchestra BioMed Holdings Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Orchestra BioMed Holdings's Pre-Tax Income
For the Biotechnology subindustry, Orchestra BioMed Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Pre-Tax Income falls into.
Orchestra BioMed Holdings Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Orchestra BioMed Holdings's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchestra BioMed Holdings (NAS:OBIO) Pre-Tax Income Explanation
Orchestra BioMed Holdings's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 4 years, Orchestra BioMed Holdings's highest Pretax Margin was 2942.97%. The lowest was -2330.46%. And the median was -662.86%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchestra BioMed Holdings Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OBIO has been successfully added to your 